Who are Bacillus Clausii Multi ATB Resist's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pro-biotics, Probiotic plus lactulose, Probiotic with Prebiotic, Gynomunal® gel, Lactobacillus casei, Lactobacillus Reuteri Probiotic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bacillus-clausii-multi-atb-resist.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bacillus Clausii Multi ATB Resist — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacillus Clausii Multi ATB Resist (Bacillus Clausii Multi ATB Resist) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

marketed Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Bacillus Clausii Multi ATB Resist (Bacillus Clausii Multi ATB Resist) — Sanofi. Bacillus clausii is a spore-forming probiotic bacterium that restores and maintains healthy gut microbiota, particularly in cases of antibiotic-associated dysbiosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Bacillus Clausii Multi ATB Resist TARGET	Bacillus Clausii Multi ATB Resist	Sanofi	marketed	Probiotic
Pro-biotics	Pro-biotics	National Cheng-Kung University Hospital	marketed	Probiotic
Probiotic plus lactulose	Probiotic plus lactulose	Qurratul Ain Jamil	marketed	Probiotic + prebiotic combination
Probiotic with Prebiotic	Probiotic with Prebiotic	Ain Shams University	marketed	Probiotic-prebiotic combination
Gynomunal® gel	Gynomunal® gel	Derming SRL	marketed	Vaginal probiotic/microbiota restorer
Lactobacillus casei	Lactobacillus casei	Hospital Cristo Re	marketed	Probiotic
Lactobacillus Reuteri Probiotic	Lactobacillus Reuteri Probiotic	Liaquat National Hospital & Medical College	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bacillus Clausii Multi ATB Resist — Competitive Intelligence Brief. https://druglandscape.com/ci/bacillus-clausii-multi-atb-resist. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab